American International Group Inc. lifted its stake in Lantheus Holdings Inc (NASDAQ:LNTH) by 14.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,147 shares of the medical equipment provider’s stock after acquiring an additional 3,101 shares during the period. American International Group Inc. owned approximately 0.06% of Lantheus worth $494,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of LNTH. Nationwide Fund Advisors bought a new stake in Lantheus during the second quarter valued at $259,000. Northern Trust Corp boosted its stake in Lantheus by 583.1% during the second quarter. Northern Trust Corp now owns 305,063 shares of the medical equipment provider’s stock valued at $5,384,000 after buying an additional 260,407 shares during the period. Vanguard Group Inc. boosted its stake in Lantheus by 87.5% during the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock valued at $26,093,000 after buying an additional 689,954 shares during the period. Dimensional Fund Advisors LP boosted its stake in Lantheus by 79.8% during the second quarter. Dimensional Fund Advisors LP now owns 524,540 shares of the medical equipment provider’s stock valued at $9,258,000 after buying an additional 232,856 shares during the period. Finally, State Street Corp boosted its stake in Lantheus by 3,932.8% during the second quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock valued at $10,891,000 after buying an additional 601,714 shares during the period. 89.55% of the stock is owned by hedge funds and other institutional investors.
In other Lantheus news, SVP Timothy G. Healey sold 3,696 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $19.58, for a total transaction of $72,367.68. Following the sale, the senior vice president now owns 64,582 shares in the company, valued at $1,264,515.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael P. Duffy sold 21,655 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $22.40, for a total value of $485,072.00. Following the sale, the insider now owns 156,784 shares in the company, valued at approximately $3,511,961.60. The disclosure for this sale can be found here. Insiders have sold 29,217 shares of company stock worth $648,368 in the last 90 days. Company insiders own 2.30% of the company’s stock.
Shares of Lantheus Holdings Inc (NASDAQ:LNTH) opened at $16.00 on Monday. The stock has a market capitalization of $600.10 and a price-to-earnings ratio of 16.33. Lantheus Holdings Inc has a 52 week low of $10.65 and a 52 week high of $24.45. The company has a debt-to-equity ratio of 11.40, a quick ratio of 2.60 and a current ratio of 3.16.
Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Monday, February 26th. The medical equipment provider reported $0.12 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.20 by ($0.08). Lantheus had a net margin of 37.23% and a negative return on equity of 68.13%. The firm had revenue of $81.24 million for the quarter, compared to analysts’ expectations of $78.57 million. During the same quarter in the previous year, the business earned $0.18 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. equities analysts expect that Lantheus Holdings Inc will post 1.04 EPS for the current fiscal year.
Several research firms recently issued reports on LNTH. Zacks Investment Research lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. BidaskClub raised Lantheus from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Finally, ValuEngine raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, February 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $24.75.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.